29.95 USD
▼-1.58-5.01%
盘后 30.24 +0.97%
2026-09-15
市值
$3.44B
市盈率
—
EPS
-4.67
股息率
—
52 周区间
22.96 – 43.15
成交量
2.81M
Beta
0.68
目标价
92.39
52W 低 22.9652W 高 43.15
价格走势
公司简介
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c...